ArticleArthritis care & research2026
Diagnostic Use of Testing for Novel Murine Autoantibodies for Sjögren Disease in the Rheumatology Outpatient Setting.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe goal was to assess the diagnostic performance of three novel autoantibodies (NA) for Sjögren disease (SjD) by comparing NA prevalence in patients with SjD, other autoimmune rheumatic diseases (ARDs), nonspecific chronic sialadenitis (CS), and controls.
methodsWe identified rheumatology outpatients with confirmed SjD, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), CS, and healthy controls. Participants underwent serum testing for antibodies to salivary gland protein 1 (SP-1), parotid secretory protein, and carbonic anhydrase-6 (CA-6). Participants with SjD, CS, and controls also underwent testing of saliva. Receiver operating characteristic (ROC) curve C-statistics along with sensitivity, specificity, positive, and negative likelihood ratios were calculated for each serum autoantibody for SjD vs CS or controls.
resultsAmong the 468 patients screened, 444 were analyzed, including cohorts with SjD (n = 149), SLE (n = 70), SSc (n = 56), RA (n = 73), CS (n = 31), and control patients (n = 65). There was no statistical difference (P = 0.80) in the presence of one or more NA in the serum of patients with SjD compared with participants with other ARDs, CS, or control patients. ROC curves demonstrated poor discriminative ability for SjD versus CS or control patients for any positive NA (0.47) or any individual NA (range 0.44-0.53). The positive likelihood ratio for having any positive novel autoantibody was 1.04 and 0.83 for SjD vs CS or control patients, respectively.
conclusionTesting serum for NA demonstrated a poor ability to distinguish patients with SjD from control patients or those with CS or other ARDs. This serum autoantibody panel is not likely to be useful as a diagnostic test for SjD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.